Casgevy is indicated for the treatment of severe sickle cell disease (SCD) in patients 12 years of age and older with recurrent vaso-occlusive crises (VOCs) for ...

Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older.

Casgevy is an autologous gene therapy medicinal product consisting of haematopoietic stem cells that have been genetically modified ex vivo. The nature of ...

Casgevy is used to treat: People aged 12 years and older with beta-thalassemia who need regular blood transfusions. People with beta-thalassemia do not have ...

CASGEVY is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). 2 DOSAGE AND ...

Summary of product characteristics (SmPC), labelling and package leaflet (PL), download. Link to the European Medicines Agency's (EMA) product information ...

23 авг. 2024 г. · This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of Exagamglogene Autotemcel.

21 февр. 2024 г. · CASGEVY indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs). Не найдено: smpc | Нужно включить: smpc

What is CASGEVY? CASGEVY is a one-time therapy used to treat people aged 12 years and older with beta thalassemia who need regular blood transfusions. Не найдено: smpc | Нужно включить: smpc

Each vial should be infused within 20 minutes of thaw. Details regarding withdrawal of Casgevy® from the vial have been outlined in the SmPC.